A protein kinase inhibitor (PKI) is a type of enzyme inhibitor that blocks the action of one or more protein kinases. [1] Protein kinases are enzymes that phosphorylate (add a phosphate , or PO 4 , group) to a protein and can modulate its function.

2025年1月31日 · There are 80 FDA-approved small molecule protein kinase inhibitors as of 2023. This enzyme family is one of the most important drug targets in the 21st century.

Blocking certain protein kinases may help keep cancer cells from growing. Some protein kinase inhibitors, such as imatinib, vemurafenib, and gefitinib, are used to treat cancer. Search NCI's Dictionary of Cancer Terms

2018年2月19日 · Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug ...

An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib.

2023年7月20日 · A protein kinase inhibitor is a type of enzyme inhibitor that can block the action of protein kinases.

This research topic delves into a comprehensive exploration of protein kinases, their metabolic pathways, and associated inhibitors. We also warmly welcome recent advances in the use of multiple protein kinase inhibitors in both anti-cancer research and therapy.

2021年7月22日 · In this study, we have addressed the role of protein kinase in human cells and the effects of protein kinase inhibitors in the treatment of various diseases and disorders. Protein kinase is a type of kinase enzyme that adds phosphate groups to other proteins chemically (i.e. phosphorylation).

2024年11月10日 · There are 82 small molecule protein kinase inhibitors and 4 antibody kinase inhibitors FDA-approved for treating cancers and other diseases (see Tables 1.1 and 1.2). There are significant numbers of small molecule kinase inhibitors in various phases of clinical trials.

In 2023, a comprehensive review highlighted the properties of 72 FDA-approved small molecule protein kinase inhibitors, noting that many of these drugs target specific kinases involved in...